Incorporating Patient Representatives into REiNS


Scott Plotkin, MD, PhD Brigitte Widemann, MD

REINS Winter Meeting December 4, 2017

What is REiNS?

Response Evaluation in NF and Schwannomatosis

 The REiNS working group is an international effort to develop standardized response criteria for determining treatment response in patients



REiNS Organizational Structure

Steering Committee:

Brigitte Widemann (NCI)

Scott Plotkin (MGH)


Jaishri Blakeley (Hopkins)

Eva Dombi (NCI)

Oliver Hanemann (Peninsula)

Karin Walsh (CNMC)

Pam Wolters (NCI)





REiNS publications 2013



Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS)

Guest Editors: Scott R. Plotkin, MD, and Brigitte C. Widemann, MD

Supplement to Neurology®

- Achieving consensus for clinical trials: The REiNS International Collaboration
- 2. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials
- 3. Functional outcome measures for NF1-associated optic pathway glioma clinical trials
- Hearing and facial function outcomes for neurofibromatosis-2 clinical trials
- 5. Recommendations for imaging tumor response in neurofibromatosis clinical trials
- Conclusions and future directions for the REiNS International Collaboration





REiNS publications 2016



Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS)

Guest Editors: Scott R. Plotkin, MD, and Brigitte C. Widemann, MD

Supplement to Neurology®






- 1. Widemann BC, Plotkin SR. Consensus for NF clinical trials: Recommendations of the REiNS collaboration (Supplement II). Neurology 2016 Aug 16;87(7 Suppl 1);S1-S3. [PDF]
- 2. Wolters PL, Martin S, Merker VL, et al. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. *Neurology* 2016 Aug 16;87(7 Suppl 1):S4-S12. [PDF]
- 3. Plotkin SR, Davis SD, Robertson KA, et al. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. *Neurology* 2016 Aug 16;87(7 Suppl 1):S13-20. [PDF]
- 4. Walsh KS, Janusz J, Wolters PL, et al. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. *Neurology* 2016 Aug 16;87(7 Suppl 1): S21-30. [PDF]
- 5. Ahlawat S, Fayad LM, Khan MS, et al. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. *Neurology* 2016 Aug 16;87(7 Suppl 1): S31-9. [PDF]
- 6. Hanemann CO, Blakeley JO, Nunes FP, et al. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology 2016 Aug 16;87(7 Suppl 1): S40-8.
 [PDF]

2016 Winter Meeting

Aims:

- To educate neurofibromatosis researchers and clinicians about the utility of increased patient engagement in developing endpoints for clinical trials.
- To engage patients, family members, and other stakeholders in the NF community in the REiNS collaboration.
- To generate a roadmap for developing patient engagement guidelines in REiNS subgroups.





2017 Winter Meeting

Aims:

- To train NF researchers and clinicians how to engage constructively with patient representatives within REiNS working groups
- To train patient representatives how to work effectively within REiNS working groups
- To update the NF community about ongoing efforts within the REiNS working groups



8:00 - 8:30 am Breakfast 8:15 am Welcome and introduction Scott Plotkin (MGH) and Brigitte Widemann (NCI) 8:30 - 9:15 am Patient-Centered Outcomes Research Institute: Mission and Funding Opportunities Parag Aggarwal, PhD FDA perspective on patient engagement 9:15 - 9:45 am Steve Morin, RN, BSN (FDA) 9:45 - 10:00 am Recruiting patient representatives to REiNS: Initial Results Scott Plotkin 10:00 - 10:30 am Training NF researchers to work with patient representatives Vanessa Merker 10:30 - 11:00 am Break



| 11:00 - 11:30 am | Training patient representatives to work with NF | |
|------------------|--|--|
| | researchers | |
| | Claas Röhl | |

11:30 – 12:00 pm CTF Patient Engagement Initiative Traceann Rose (Children's Tumor Foundation)

12:00 – 1:30 pm Patient representative introduction Lunch at local venues

1:30 – 3:00 pm Working group presentations (7 minutes each) REiNS Members

3:00 – 5:00 pm Working group meetings including NF researchers and Patient Representatives

5:00 - 5:30 pm Informal working group reports

5:30-6:00 pm Networking and informal discussions



Working group sessions

| | 3 – 4 pm | 4 – 5 pm |
|--------|----------------|----------------|
| Area 1 | PRO | PRO |
| Area 2 | Functional | Biomarkers |
| Area 3 | Tumor Imaging | WBMRI |
| Area 4 | Neurocognitive | Neurocognitive |
| Area 5 | Cutaneous NF | Cutaneous NF |



Acknowledgements



Vanessa Merker



Anna Maria Benigni

Elise Mongeon (ASL interpreter) Lisette Madalena (ASL interpreter)



NCI grant R13 TR002095-02 (NCATS) Children's Tumor Foundation

Social Media

Twitter: @REiNScollab

REINS Winter 2017 MeetingMon, Dec 4, 2017 7:45 AM - 3:45 PM EST

Please join my meeting from your computer, tablet or smartphone.

https://global.gotomeeting.com/join/451021245

You can also dial in using your phone.

United States: +1 (786) 535-3219

Access Code: 451-021-245

More phone numbers

United Kingdom: +44 20 3713 5028



Future directions

- November 2018 meeting in Paris, France
- Continued development of outcomes measures in each working group
- New working group
 - Patient representation
- REINS Website (https://ccrod.cancer.gov/confluence/display/ REINS/_)
- Apply for funding through PCORI to support patient engagement



Feedback

- Please fill out evaluation forms to help improve REiNS winter meeting
 - Needed for R13 competitive renewal in 2/2018



Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS)

- Imaging response (Widemann, Dombi)
- Functional outcomes (Plotkin)
- Patient reported outcomes (Wolters)
- Whole body MRI (Ahlawat)
- Visual outcomes (Fisher)
- Neurocognitive outcomes (Walsh)
- Biomarkers (Hanemann)

The REiNS working groups are open to all participants











- 7 working groups
- >75 active members